

PE/Dazzle™ 594 anti-mouse CD304 (Neuropilin-1)

Catalog # / 1326085 / 25 µg
Size: 1326090 / 100 µg

Clone: 3E12

Isotype: Rat IgG2a, κ


Immunogen: Extracellular region of mouse CD304

Reactivity: Mouse

Preparation: The antibody was purified by affinity chromatography and conjugated with PE/Dazzle™ 594 under optimal conditions. The solution is free of unconjugated PE/Dazzle™ 594 and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Concentration: 0.2 mg/ml



C57BL/6 mouse splenocytes were stained with CD4 APC and CD304 (Neuropilin-1) (clone 3E12) PE/Dazzle™ 594 (left) or Rat IgG2a, κ PE/Dazzle™ 594 isotype control (right).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.125 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

* PE/Dazzle™ 594 has a maximum excitation of 566 nm and a maximum emission of 610 nm.

Application References:

1. Blankenhau B, *et al.* 2014. *PLoS Pathog.* 10:1003913. [PubMed](#)
2. Verhagen J and Wraith DC. 2014. *J. Immunol. Methods.* S0022. (FC) [PubMed](#)
3. Verhagen J, *et al.* 2014. *PLoS One.* 9e:108023. (FC) [PubMed](#)

Description: CD304, also known as neuropilin-1, is a 140 kD type I transmembrane protein. Its extracellular region contains two CUB, two FV/FVIII, and one MAM domain. It is expressed by natural regulatory T cells (nTreg), a subset of invariant natural killer T cells (iNKT), endothelial cells, and neurons. Neuropilin-1 stabilizes the interaction between Tregs and dendritic cells, contributes to the recruitment of tumor-infiltrating Tregs in response to tumor-derived VEGF, and influences the process of angiogenesis and axon guidance. The ligands of CD304 are VEGF165 and semaphorin-3A.

Antigen References:

1. Yadav M, *et al.* 2012. *J. Exp. Med.* 209:1713.
2. Weiss JM, *et al.* 2012. *J. Exp. Med.* 209:1723.
3. Hansen W, *et al.* 2012. *J. Exp. Med.* 209:2001.
4. Milpied P, *et al.* 2011. *Blood* 118:2993.